|
May 14
|
Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals
|
|
May 10
|
Struggling 23andMe Granted Extension to Revive Stock Price
|
|
May 9
|
23andMe to Report Q4 and Full Year FY2024 Financial Results
|
|
Apr 26
|
7 Best Sites Like Ancestry.com to Research Your Family History
|
|
Apr 24
|
23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
|
|
Apr 23
|
This Technology Company Is Being Acquired at a Shocking 207% Premium -- and These 2 Stocks Could Be Next
|
|
Apr 19
|
23andMe CEO Anne Wojcicki Says She’s Weighing Buyout Bid
|
|
Apr 18
|
Stocks to Watch Thursday: TSMC, Netflix, Nvidia, Tesla
|
|
Apr 18
|
23andMe Stock Jumps on News of Plans to Take It Private
|
|
Apr 18
|
23andMe CEO Anne Wojcicki Plans to Take Company Private
|
|
Apr 18
|
23andMe Jumps as CEO Floats Taking DNA Tester Private
|
|
Apr 18
|
23andMe announces CEO’s intention to pursue a potential take-private
|
|
Apr 18
|
23andMe CEO plans to take company private
|
|
Apr 18
|
23andMe CEO Wojcicki considering taking firm private, filing shows
|
|
Apr 17
|
Can 23andMe Holding (NASDAQ:ME) Afford To Invest In Growth?
|
|
Apr 5
|
23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
|
|
Mar 24
|
Billionaires Are Snapping Up Beaten-Down 23andMe Stock. Should You Follow Their Lead?
|
|
Mar 20
|
23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
|
|
Mar 19
|
23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years Ago
|
|
Mar 6
|
23andMe Launches New Genetic Reports on Common Forms of Cancer
|